Thyroid orbitopathy

References

• Naik VM, Naik MN, Goldberg RA, Smith TJ, Douglas RS. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv. Ophthalmol. 55(3), 215–226 (2010).
   PubMed Web of Science ®Google Scholar
• Bürgi H. Thyroid eye disease: a historical perspective. Orbit 28(4), 226–230 (2009).
   PubMedGoogle Scholar
• Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves’ ophthalmopathy. Thyroid 12(10), 855–860 (2002).
   PubMed Web of Science ®Google Scholar
• Bartley GB, Fatourechi V, Kadrmas EF et al. The incidence of Graves’ ophthalmopathy in Olmsted County, Minnesota. Am. J. Ophthalmol. 120(4), 511–517 (1995).
   PubMed Web of Science ®Google Scholar
• Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A. Studies on the occurrence of ophthalmopathy in Graves’ disease. Acta Endocrinol. 120(4), 473–478 (1989).
   PubMedGoogle Scholar
• Burch HB, Wartofsky L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr. Rev. 14(6), 747–793 (1993).
   PubMed Web of Science ®Google Scholar
• Gleeson H, Kelly W, Toft A et al. Severe thyroid eye disease associated with primary hypothyroidism and thyroid-associated dermopathy. Thyroid 9(11), 1115–1118 (1999).
   PubMed Web of Science ®Google Scholar
• Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy. Endocr. Rev. 24(6), 802–835 (2003).
   PubMed Web of Science ®Google Scholar
• Vaidya B, Oakes EJ, Imrie H et al. CTLA4 gene and Graves’ disease: association of Graves’ disease with the CTLA4 exon 1 and intron 1 polymorphisms, but not with the promoter polymorphism. Clin. Endocrinol. (Oxf.) 58(6), 732–735 (2003).
   PubMed Web of Science ®Google Scholar
• Dechairo BM, Zabaneh D, Collins J et al. Association of the TSHR gene with Graves’ disease: the first disease specific locus. Eur. J. Hum. Genet. 13(11), 1223–1230 (2005).
   PubMed Web of Science ®Google Scholar
• Han S, Zhang S, Zhang W et al. CTLA4 polymorphisms and ophthalmopathy in Graves’ disease patients: association study and meta-analysis. Hum. Immunol. 67(8), 618–626 (2006).
   PubMed Web of Science ®Google Scholar
• Brand OJ, Barrett JC, Simmonds MJ et al. Association of the thyroid stimulating hormone receptor gene (TSHR) with Graves’ disease. Hum. Mol. Genet. 18(9), 1704–1713 (2009).
   PubMed Web of Science ®Google Scholar
• Cawood TJ, Moriarty P, O’Farrelly C, O’Shea D. Smoking and thyroid-associated ophthalmopathy: a novel explanation of the biological link. J. Clin. Endocrinol. Metab. 92(1), 59–64 (2007).
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves’ ophthalmopathy after radioiodine treatment? Eur. J. Endocrinol. 130(5), 494–497 (1994).
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Campi I, Covelli D et al. Graves’ orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. J. Clin. Endocrinol. Metab. 94, 3381–3386 (2009).
   PubMed Web of Science ®Google Scholar
• Bahn RS, Burch HB, Cooper DS et al.; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr. Pract. 17(3), 456–520 (2011).
   PubMed Web of Science ®Google Scholar
• Lai A, Sassi L, Compri E et al. Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves’ orbitopathy: a retrospective cohort study. J. Clin. Endocrinol. Metab. 95(3), 1333–1337 (2010).
   PubMed Web of Science ®Google Scholar
• Rundle FF. Management of exophthalmos and related ocular changes in Graves’ disease. Metab. Clin. Exp. 6(1), 36–48 (1957).
   PubMed Web of Science ®Google Scholar
• Bartley GB, Gorman CA. Diagnostic criteria for Graves’ ophthalmopathy. Am. J. Ophthalmol. 119(6), 792–795 (1995).
   PubMed Web of Science ®Google Scholar
• Khan JA, Doane JF, Whitacre MM. Does decompression diminish the discomfort of severe dysthyroid orbitopathy? Ophthal. Plast. Reconstr. Surg. 11(2), 109–112 (1995).
   PubMed Web of Science ®Google Scholar
• Villani E, Viola F, Sala R et al. Corneal involvement in Graves’ orbitopathy: an in vivo confocal study. Invest. Ophthalmol. Vis. Sci. 51(9), 4574–4578 (2010).
   PubMed Web of Science ®Google Scholar
• Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R. Clinical criteria for the assessment of disease activity in Graves’ ophthalmopathy: a novel approach. Br. J. Ophthalmol. 73(8), 639–644 (1989).
   PubMed Web of Science ®Google Scholar
• Nugent RA, Belkin RI, Neigel JM et al. Graves orbitopathy: correlation of CT and clinical findings. Radiology 177(3), 675–682 (1990).
   PubMed Web of Science ®Google Scholar
• Regensburg NI, Wiersinga WM, Berendschot TT, Potgieser P, Mourits MP. Do subtypes of Graves’ orbitopathy exist? Ophthalmology 118(1), 191–196 (2011).
   PubMed Web of Science ®Google Scholar
• Neigel JM, Rootman J, Belkin RI et al. Dysthyroid optic neuropathy. The crowded orbital apex syndrome. Ophthalmology 95(11), 1515–1521 (1988).
   PubMed Web of Science ®Google Scholar
• Weis E, Heran MK, Jhamb A et al. Clinical and soft-tissue computed tomographic predictors of dysthyroid optic neuropathy: refinement of the constellation of findings at presentation. Arch. Ophthalmol. 129(10), 1332–1336 (2011).
   PubMedGoogle Scholar
• da Silva FL, de Lourdes Veronese Rodrigues M, Akaishi PM, Cruz AA. Graves’ orbitopathy: frequency of ocular hypertension and glaucoma. Eye (Lond.) 23(4), 957–959 (2009).
   PubMed Web of Science ®Google Scholar
• Pinchera A, Glinoer D, Kendall-Taylor P et al. Classification of eye changes of Graves’ disease. Thyroid 2(3), 235–236 (1992).
   PubMed Web of Science ®Google Scholar
• Dickinson AJ, Perros P. Controversies in the clinical evaluation of active thyroid-associated orbitopathy: use of a detailed protocol with comparative photographs for objective assessment. Clin. Endocrinol. (Oxf.) 55(3), 283–303 (2001).
   PubMed Web of Science ®Google Scholar
• Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf.) 47(1), 9–14 (1997).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson AJ et al. Consensus statement of the European group on Graves’ orbitopathy (EUGOGO) on management of Graves’ orbitopathy. Thyroid 18(3), 333–346 (2008).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Tanda ML. Clinical practice. Graves’ ophthalmopathy. N. Engl. J. Med. 360(10), 994–1001 (2009).
   PubMed Web of Science ®Google Scholar
• Prummel MF, Gerding MN, Zonneveld FW, Wiersinga WM. The usefulness of quantitative orbital magnetic resonance imaging in Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf.) 54(2), 205–209 (2001).
   PubMed Web of Science ®Google Scholar
• Gerding MN, van der Meer JW, Broenink M, Bakker O, Wiersinga WM, Prummel MF. Association of thyrotrophin receptor antibodies with the clinical features of Graves’ ophthalmopathy. Clin. Endocrinol. (Oxf.) 52(3), 267–271 (2000).
   PubMed Web of Science ®Google Scholar
• Eckstein AK, Plicht M, Lax H et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol. Metab. 91(9), 3464–3470 (2006).
   PubMed Web of Science ®Google Scholar
• Ponto KA, Kanitz M, Olivo PD, Pitz S, Pfeiffer N, Kahaly GJ. Clinical relevance of thyroid-stimulating immunoglobulins in Graves’ ophthalmopathy. Ophthalmology 118(11), 2279–2285 (2011).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Pinchera A, Marcocci C. Management of Graves’ ophthalmopathy: reality and perspectives. Endocr. Rev. 21(2), 168–199 (2000).
   PubMed Web of Science ®Google Scholar
• Dolman PJ, Rootman J. VISA Classification for Graves orbitopathy. Ophthal. Plast. Reconstr. Surg. 22(5), 319–324 (2006).
   PubMed Web of Science ®Google Scholar
• Bartalena L, Baldeschi L, Dickinson A et al.; European Group on Graves’ Orbitopathy (EUGOGO). Consensus statement of the European Group on Graves’ orbitopathy (EUGOGO) on management of GO. Eur. J. Endocrinol. 158(3), 273–285 (2008).
   PubMed Web of Science ®Google Scholar
• Just M, Kahaly G, Higer HP et al. Graves ophthalmopathy: role of MR imaging in radiation therapy. Radiology 179(1), 187–190 (1991).
   PubMed Web of Science ®Google Scholar
• Birchall D, Goodall KL, Noble JL, Jackson A. Graves ophthalmopathy: intracranial fat prolapse on CT images as an indicator of optic nerve compression. Radiology 200(1), 123–127 (1996).
   PubMed Web of Science ®Google Scholar
• Ohnishi T, Noguchi S, Murakami N et al. Extraocular muscles in Graves ophthalmopathy: usefulness of T2 relaxation time measurements. Radiology 190(3), 857–862 (1994).
   PubMed Web of Science ®Google Scholar
• Mayer EJ, Fox DL, Herdman G et al. Signal intensity, clinical activity and cross-sectional areas on MRI scans in thyroid eye disease. Eur. J. Radiol. 56(1), 20–24 (2005).
   PubMed Web of Science ®Google Scholar
• Alp MN, Ozgen A, Can I, Cakar P, Gunalp I. Colour Doppler imaging of the orbital vasculature in Graves’ disease with computed tomographic correlation. Br. J. Ophthalmol. 84(9), 1027–1030 (2000).
   PubMed Web of Science ®Google Scholar
• Benning H, Lieb W, Kahaly G, Grehn F. [Color duplex ultrasound findings in patients with endocrine orbitopathy]. Ophthalmologe 91(1), 20–25 (1994).
   PubMedGoogle Scholar
• Nakase Y, Osanai T, Yoshikawa K, Inoue Y. Color Doppler imaging of orbital venous flow in dysthyroid optic neuropathy. Jpn. J. Ophthalmol. 38(1), 80–86 (1994).
   PubMed Web of Science ®Google Scholar
• Konuk O, Onaran Z, Ozhan Oktar S, Yucel C, Unal M. Intraocular pressure and superior ophthalmic vein blood flow velocity in Graves’ orbitopathy: relation with the clinical features. Graefes Arch. Clin. Exp. Ophthalmol. 247(11), 1555–1559 (2009).
   PubMed Web of Science ®Google Scholar
• Monteiro ML, Angotti-Neto H, Benabou JE, Betinjane AJ. Color Doppler imaging of the superior ophthalmic vein in different clinical forms of Graves’ orbitopathy. Jpn. J. Ophthalmol. 52(6), 483–488 (2008).
   PubMed Web of Science ®Google Scholar
• Yanik B, Conkbayir I, Acaroglu G, Hekimoglu B. Graves’ ophthalmopathy: comparison of the Doppler sonography parameters with the clinical activity score. J. Clin. Ultrasound 33(8), 375–380 (2005).
   PubMed Web of Science ®Google Scholar
• Pérez-López M, Sales-Sanz M, Rebolleda G et al. Retrobulbar ocular blood flow changes after orbital decompression in Graves’ ophthalmopathy measured by color Doppler imaging. Invest. Ophthalmol. Vis. Sci. 52(8), 5612–5617 (2011).
   PubMed Web of Science ®Google Scholar
• Lehmann GM, Feldon SE, Smith TJ, Phipps RP. Immune mechanisms in thyroid eye disease. Thyroid 18(9), 959–965 (2008).
   PubMed Web of Science ®Google Scholar
• Papageorgiou KI, Hwang CJ, Chang SH et al. Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy. Arch. Ophthalmol. 130(3), 319–328 (2012).
   PubMedGoogle Scholar
• Douglas RS, Afifiyan NF, Hwang CJ et al. Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 95(1), 430–438 (2010).
   PubMed Web of Science ®Google Scholar
• Douglas RS, Gupta S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr. Opin. Ophthalmol. 22(5), 385–390 (2011).
   PubMed Web of Science ®Google Scholar
• Gerding MN, Terwee CB, Dekker FW, Koornneef L, Prummel MF, Wiersinga WM. Quality of life in patients with Graves’ ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument. Thyroid 7(6), 885–889 (1997).
   PubMed Web of Science ®Google Scholar
• Marcocci C, Kahaly GJ, Krassas GE et al.; European Group on Graves’ Orbitopathy. Selenium and the course of mild Graves’ orbitopathy. N. Engl. J. Med. 364(20), 1920–1931 (2011).
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves’ orbitopathy. J. Clin. Endocrinol. Metab. 90(9), 5234–5240 (2005).
   PubMed Web of Science ®Google Scholar
• Kahaly GJ, Rösler HP, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves’ ophthalmopathy: a randomized, single blind trial. J. Clin. Endocrinol. Metab. 85(1), 102–108 (2000).
   PubMed Web of Science ®Google Scholar
• Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid eye disease. Thyroid 10(6), 521 (2000).
   PubMed Web of Science ®Google Scholar
• Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves’ ophthalmopathy. Thyroid 17(4), 357–362 (2007).
   PubMed Web of Science ®Google Scholar
• Kazim M, Garrity JA. Orbital radiation therapy for thyroid eye disease. J. Neuroophthalmol. 32(2), 172–176 (2012).
   PubMed Web of Science ®Google Scholar
• Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves’ ophthalmopathy: systematic review and metaanalysis. J. Clin. Endocrinol. Metab. 94(8), 2708–2716 (2009).
   PubMed Web of Science ®Google Scholar
• Bartalena L. What to do for moderate-to-severe and active Graves’ orbitopathy if glucocorticoids fail? Clin. Endocrinol. (Oxf.) 73(2), 149–152 (2010).
   PubMed Web of Science ®Google Scholar
• Ebner R, Devoto MH, Weil D et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br. J. Ophthalmol. 88(11), 1380–1386 (2004).
   PubMed Web of Science ®Google Scholar
• Zang S, Ponto KA, Kahaly GJ. Clinical review: intravenous glucocorticoids for Graves’ orbitopathy: efficacy and morbidity. J. Clin. Endocrinol. Metab. 96(2), 320–332 (2011).
   PubMed Web of Science ®Google Scholar
• Hart RH, Kendall-Taylor P, Crombie A, Perros P. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J. Ocul. Pharmacol. Ther. 21(4), 328–336 (2005).
   PubMed Web of Science ®Google Scholar
• Dickinson AJ, Vaidya B, Miller M et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J. Clin. Endocrinol. Metab. 89(12), 5910–5915 (2004).
   PubMed Web of Science ®Google Scholar
• Wémeau JL, Caron P, Beckers A et al. Octreotide (long-acting release formulation) treatment in patients with Graves’ orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J. Clin. Endocrinol. Metab. 90(2), 841–848 (2005).
   PubMed Web of Science ®Google Scholar
• Chang TC, Liao SL. Slow-release lanreotide in Grave’s ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J. Endocrinol. Invest. 29(5), 413–422 (2006).
   PubMed Web of Science ®Google Scholar
• Stan MN, Garrity JA, Bradley EA et al. Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves’ ophthalmopathy. J. Clin. Endocrinol. Metab. 91(12), 4817–4824 (2006).
   PubMed Web of Science ®Google Scholar
• Kahaly G, Schrezenmeir J, Krause U et al. Ciclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur. J. Clin. Invest. 16(5), 415–422 (1986).
   PubMed Web of Science ®Google Scholar
• Prummel MF, Mourits MP, Berghout A et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N. Engl. J. Med. 321(20), 1353–1359 (1989).
   PubMed Web of Science ®Google Scholar
• Bonara P, Vannucchi G, Campi I et al. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves’ ophthalmopathy. Clin. Rev. Allergy Immunol. 34(1), 118–123 (2008).
   PubMed Web of Science ®Google Scholar
• Nielsen JF, El Fassi D, Nielsen CH et al. Evidence of orbital B and T cell depletion after rituximab therapy in Graves’ ophthalmopathy. Acta Ophthalmol. 87(8), 927–929 (2009).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I, Beck-Peccoz P. Rituximab in the treatment of thyroid eye disease: science fiction? Orbit 28(4), 251–255 (2009).
   PubMedGoogle Scholar
• El Fassi D, Banga JP, Gilbert JA, Padoa C, Hegedüs L, Nielsen CH. Treatment of Graves’ disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies. Clin. Immunol. 130(3), 252–258 (2009).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Currò N et al. Small dose of rituximab for Graves orbitopathy: new insights into the mechanism of action. Arch. Ophthalmol. 130(1), 122–124 (2012).
   PubMedGoogle Scholar
• El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves’ disease: a controlled pilot study. J. Clin. Endocrinol. Metab. 92(5), 1769–1772 (2007).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. 156(1), 33–40 (2007).
   PubMed Web of Science ®Google Scholar
• Heemstra KA, Toes RE, Sepers J et al. Rituximab in relapsing Graves’ disease, a Phase II study. Eur. J. Endocrinol. 159(5), 609–615 (2008).
   PubMed Web of Science ®Google Scholar
• Silkiss RZ, Reier A, Coleman M, Lauer SA. Rituximab for thyroid eye disease. Ophthal. Plast. Reconstr. Surg. 26(5), 310–314 (2010).
   PubMed Web of Science ®Google Scholar
• Vannucchi G, Campi I, Bonomi M et al. Rituximab treatment in patients with active Graves’ orbitopathy: effects on proinflammatory and humoral immune reactions. Clin. Exp. Immunol. 161(3), 436–443 (2010).
   PubMed Web of Science ®Google Scholar
• Salvi M, Vannucchi G, Campi I et al. Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin. Immunol. 131(2), 360–365 (2009).
   PubMed Web of Science ®Google Scholar
• Teixeira A, Chong LP, Matsuoka N et al. Vitreoretinal traction created by conventional cutters during vitrectomy. Ophthalmology 117(7), 1387.e2–1392.e2 (2010).
   Web of Science ®Google Scholar
• Madaschi S, Rossini A, Formenti I et al. Treatment of thyroid-associated orbitopathy with rituximab – a novel therapy for an old disease: case report and literature review. Endocr. Pract. 16(4), 677–685 (2010).
   PubMed Web of Science ®Google Scholar
• Krassas GE, Stafilidou A, Boboridis KG. Failure of rituximab treatment in a case of severe thyroid ophthalmopathy unresponsive to steroids. Clin. Endocrinol. (Oxf.) 72(6), 853–855 (2010).
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113(20), 4834–4840 (2009).
   PubMed Web of Science ®Google Scholar
• Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves’ ophthalmopathy: a pilot study. Eye (Lond.) 19(12), 1286–1289 (2005).
   PubMed Web of Science ®Google Scholar
• Filippopoulos T, Hanna E, Chen TC, Grosskreutz CL, Jakobiec FA, Pasquale LR. Correlation of filtration bleb morphology with histology. Int. Ophthalmol. Clin. 49, 71–82 (2009).
   PubMedGoogle Scholar
• Baldeschi L, Wakelkamp IM, Lindeboom R, Prummel MF, Wiersinga WM. Early versus late orbital decompression in Graves’ orbitopathy: a retrospective study in 125 patients. Ophthalmology 113(5), 874–878 (2006).
   PubMed Web of Science ®Google Scholar
• Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves’ ophthalmopathy. Am. J. Ophthalmol. 135(3), 285–290 (2003).
   PubMed Web of Science ®Google Scholar
• Ebner R. Botulinum toxin type A in upper lid retraction of Graves’ ophthalmopathy. J. Clin. Neuroophthalmol. 13(4), 258–261 (1993).
   PubMedGoogle Scholar
• Maino AP, Dawson EL, Adams GG, Rose GE, Lee JP. The management of patients with thyroid eye disease after bilateral orbital 3 wall decompression. Strabismus 19(2), 35–37 (2011).
   PubMedGoogle Scholar
• Rose GE. Postural visual obscurations in patients with inactive thyroid eye disease; a variant of ‘hydraulic’ disease. Eye (Lond.) 20(10), 1178–1185 (2006).
   PubMed Web of Science ®Google Scholar
• Baldeschi L, MacAndie K, Koetsier E, Blank LE, Wiersinga WM. The influence of previous orbital irradiation on the outcome of rehabilitative decompression surgery in Graves orbitopathy. Am. J. Ophthalmol. 145(3), 534–540 (2008).
   PubMed Web of Science ®Google Scholar
• Mourits MP, Bijl H, Altea MA et al. Outcome of orbital decompression for disfiguring proptosis in patients with Graves’ orbitopathy using various surgical procedures. Br. J. Ophthalmol. 93(11), 1518–1523 (2009).
   PubMed Web of Science ®Google Scholar
• McCann JD, Goldberg RA, Anderson RL, Burroughs JR, Ben Simon GJ. Medial wall decompression for optic neuropathy but lateral wall decompression with fat removal for non vision-threatening indications. Am. J. Ophthalmol. 141(5), 916–917 (2006).
   PubMed Web of Science ®Google Scholar
• Chang EL, Bernardino CR, Rubin PA. Transcaruncular orbital decompression for management of compressive optic neuropathy in thyroid-related orbitopathy. Plast. Reconstr. Surg. 112(3), 739–747 (2003).
   PubMed Web of Science ®Google Scholar
• Perry JD, Kadakia A, Foster JA. Transcaruncular orbital decompression for dysthyroid optic neuropathy. Ophthal. Plast. Reconstr. Surg. 19(5), 353–358 (2003).
   PubMed Web of Science ®Google Scholar
• Liao SL, Chang TC, Lin LL. Transcaruncular orbital decompression: an alternate procedure for Graves ophthalmopathy with compressive optic neuropathy. Am. J. Ophthalmol. 141(5), 810–818 (2006).
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Perry JD, Hortaleza V, Tong JT. Strabismus after balanced medial plus lateral wall versus lateral wall only orbital decompression for dysthyroid orbitopathy. Ophthal. Plast. Reconstr. Surg. 16(4), 271–277 (2000).
   PubMed Web of Science ®Google Scholar
• Kazim M, Trokel SL, Acaroglu G, Elliott A. Reversal of dysthyroid optic neuropathy following orbital fat decompression. Br. J. Ophthalmol. 84(6), 600–605 (2000).
   PubMed Web of Science ®Google Scholar
• Boboridis KG, Bunce C. Surgical orbital decompression for thyroid eye disease. Cochrane Database Syst. Rev. 12, CD007630 (2011).
   Google Scholar
• Garrity JA, Fatourechi V, Bergstralh EJ et al. Results of transantral orbital decompression in 428 patients with severe Graves’ ophthalmopathy. Am. J. Ophthalmol. 116(5), 533–547 (1993).
   PubMed Web of Science ®Google Scholar
• Norris JH, Ross JJ, O’Reilly P, Malhotra R. A review of combined orbital decompression and lower eyelid recession surgery for lower eyelid retraction in thyroid orbitopathy. Br. J. Ophthalmol. 95(12), 1664–1669 (2011).
   PubMed Web of Science ®Google Scholar
• Tallstedt L. Surgical treatment of thyroid eye disease. Thyroid 8(5), 447–452 (1998).
   PubMed Web of Science ®Google Scholar
• Tallstedt L, Papatziamos G, Lundblad L, Anggård A. Results of transantral orbital decompression in patients with thyroid-associated ophthalmopathy. Acta Ophthalmol. Scand. 78(2), 206–210 (2000).
   PubMedGoogle Scholar
• Cruz AA, Leme VR. Orbital decompression: a comparison between trans-fornix/transcaruncular inferomedial and coronal inferomedial plus lateral approaches. Ophthal. Plast. Reconstr. Surg. 19(6), 440–445; discussion 445 (2003).
   PubMed Web of Science ®Google Scholar
• Kennedy DW, Goodstein ML, Miller NR, Zinreich SJ. Endoscopic transnasal orbital decompression. Arch. Otolaryngol. Head Neck Surg. 116(3), 275–282 (1990).
   PubMedGoogle Scholar
• Wright ED, Davidson J, Codere F, Desrosiers M. Endoscopic orbital decompression with preservation of an inferomedial bony strut: minimization of postoperative diplopia. J. Otolaryngol. 28(5), 252–256 (1999).
   PubMedGoogle Scholar
• White WA, White WL, Shapiro PE. Combined endoscopic medial and inferior orbital decompression with transcutaneous lateral orbital decompression in Graves’ orbitopathy. Ophthalmology 110(9), 1827–1832 (2003).
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Shorr N, Cohen MS. The medical orbital strut in the prevention of postdecompression dystopia in dysthyroid ophthalmopathy. Ophthal. Plast. Reconstr. Surg. 8(1), 32–34 (1992).
   PubMed Web of Science ®Google Scholar
• Mourits MP, Koorneef L, van Mourik-Noordenbos AM et al. Extraocular muscle surgery for Graves’ ophthalmopathy: does prior treatment influence surgical outcome? Br. J. Ophthalmol. 74(8), 481–483 (1990).
   PubMed Web of Science ®Google Scholar
• Paridaens D, Hans K, van Buitenen S, Mourits MP. The incidence of diplopia following coronal and translid orbital decompression in Graves’ orbitopathy. Eye (Lond.) 12(Pt 5), 800–805 (1998).
   PubMed Web of Science ®Google Scholar
• George JL, Tercero ME, Angioï-Duprez K, Maalouf T. Risk of dry eye after Müllerectomy via the posterior conjunctival approach for thyroid-related upper eyelid retraction. Orbit 21(1), 19–25 (2002).
   PubMedGoogle Scholar
• Siracuse-Lee DE, Kazim M. Orbital decompression: current concepts. Curr. Opin. Ophthalmol. 13(5), 310–316 (2002).
   PubMedGoogle Scholar
• Paridaens D, Lie A, Grootendorst RJ, van den Bosch WA. Efficacy and side effects of ‘swinging eyelid’ orbital decompression in Graves’ orbitopathy: a proposal for standardized evaluation of diplopia. Eye (Lond). 20(2), 154–162 (2006).
   PubMed Web of Science ®Google Scholar
• Leone CR Jr, Piest KL, Newman RJ. Medial and lateral wall decompression for thyroid ophthalmopathy. Am. J. Ophthalmol. 108(2), 160–166 (1989).
   PubMed Web of Science ®Google Scholar
• Shepard KG, Levin PS, Terris DJ. Balanced orbital decompression for Graves’ ophthalmopathy. Laryngoscope 108(11 Pt 1), 1648–1653 (1998).
   PubMed Web of Science ®Google Scholar
• Graham SM, Brown CL, Carter KD, Song A, Nerad JA. Medial and lateral orbital wall surgery for balanced decompression in thyroid eye disease. Laryngoscope 113(7), 1206–1209 (2003).
   PubMed Web of Science ®Google Scholar
• Alsuhaibani AH, Carter KD, Policeni B, Nerad JA. Orbital volume and eye position changes after balanced orbital decompression. Ophthal. Plast. Reconstr. Surg. 27(3), 158–163 (2011).
   PubMed Web of Science ®Google Scholar
• Baldeschi L, MacAndie K, Hintschich C, Wakelkamp IM, Prummel MF, Wiersinga WM. The removal of the deep lateral wall in orbital decompression: its contribution to exophthalmos reduction and influence on consecutive diplopia. Am. J. Ophthalmol. 140(4), 642–647 (2005).
   PubMed Web of Science ®Google Scholar
• Paridaens DA, Verhoeff K, Bouwens D, van Den Bosch WA. Transconjunctival orbital decompression in Graves’ ophthalmopathy: lateral wall approach ab interno. Br. J. Ophthalmol. 84(7), 775–781 (2000).
   PubMed Web of Science ®Google Scholar
• Chang EL, Piva AP. Temporal fossa orbital decompression for treatment of disfiguring thyroid-related orbitopathy. Ophthalmology 115(9), 1613–1619 (2008).
   PubMed Web of Science ®Google Scholar
• Mehta P, Durrani OM. Outcome of deep lateral wall rim-sparing orbital decompression in thyroid-associated orbitopathy: a new technique and results of a case series. Orbit 30(6), 265–268 (2011).
   PubMedGoogle Scholar
• Kakizaki H, Takahashi Y, Ichinose A, Iwaki M, Selva D, Leibovitch I. The importance of rim removal in deep lateral orbital wall decompression. Clin. Ophthalmol. 5, 865–869 (2011).
   PubMedGoogle Scholar
• Millar MJ, Maloof AJ. The application of stereotactic navigation surgery to orbital decompression for thyroid-associated orbitopathy. Eye (Lond.) 23(7), 1565–1571 (2009).
   PubMed Web of Science ®Google Scholar
• Boboridis KG, Gogakos A, Krassas GE. Orbital fat decompression for Graves’ orbitopathy: a literature review. Pediatr. Endocrinol. Rev. 7(Suppl. 2), 222–226 (2010).
   PubMedGoogle Scholar
• Rajendram R, Bunce C, Adams GG, Dayan CM, Rose GE. Smoking and strabismus surgery in patients with thyroid eye disease. Ophthalmology 118(12), 2493–2497 (2011).
   PubMed Web of Science ®Google Scholar
• Kraus DJ, Bullock JD. Treatment of thyroid ocular myopathy with adjustable and nonadjustable suture strabismus surgery. Trans. Am. Ophthalmol. Soc. 91, 67–79; discussion 79 (1993).
   PubMedGoogle Scholar
• Dal Canto AJ, Crowe S, Perry JD, Traboulsi EI. Intraoperative relaxed muscle positioning technique for strabismus repair in thyroid eye disease. Ophthalmology 113(12), 2324–2330 (2006).
   PubMed Web of Science ®Google Scholar
• Köse S, Uretmen O, Emre S, Pamukcu K. Recession of the inferior rectus muscle under topical anesthesia in thyroid ophthalmopathy. J. Pediatr. Ophthalmol. Strabismus 39(6), 331–335 (2002).
   PubMed Web of Science ®Google Scholar
• Bok C, Hidalgo C, Morax S. [Surgical management of diplopia in dysthyroid orbitopathy]. J. Fr. Ophtalmol. 30(4), 390–396 (2007).
   PubMed Web of Science ®Google Scholar
• Nardi M. Squint surgery in TED – hints and fints, or why Graves’ patients are difficult patients. Orbit 28(4), 245–250 (2009).
   PubMedGoogle Scholar
• Nassar MM, Dickinson AJ, Neoh C et al. Parameters predicting outcomes of strabismus surgery in the management of Graves’ ophthalmopathy. J. AAPOS 13(3), 236–240 (2009).
   PubMed Web of Science ®Google Scholar
• Oguz V, Yolar M, Pazarli H. Extraocular muscle surgery in dysthyroid orbitomyopathy: influence of previous conditions on surgical results. J. Pediatr. Ophthalmol. Strabismus 39(2), 77–80 (2002).
   PubMed Web of Science ®Google Scholar
• Gomi CF, Yang SW, Granet DB et al. Change in proptosis following extraocular muscle surgery: effects of muscle recession in thyroid-associated orbitopathy. J. AAPOS 11(4), 377–380 (2007).
   PubMed Web of Science ®Google Scholar
• Putterman AM, Urist M. Surgical treatment of upper eyelid retraction. Arch. Ophthalmol. 87(4), 401–405 (1972).
   PubMedGoogle Scholar
• Buffam FV, Rootman J. Lid retraction – its diagnosis and treatment. Int. Ophthalmol. Clin. 18(3), 75–86 (1978).
   PubMedGoogle Scholar
• Ben Simon GJ, Mansury AM, Schwarcz RM, Lee S, McCann JD, Goldberg RA. Simultaneous orbital decompression and correction of upper eyelid retraction versus staged procedures in thyroid-related orbitopathy. Ophthalmology 112(5), 923–932 (2005).
   PubMed Web of Science ®Google Scholar
• Mourits MP, Sasim IV. A single technique to correct various degrees of upper lid retraction in patients with Graves’ orbitopathy. Br. J. Ophthalmol. 83(1), 81–84 (1999).
   PubMed Web of Science ®Google Scholar
• Grove AS Jr. Eyelid retraction treated by levator marginal myotomy. Ophthalmology 87(10), 1013–1018 (1980).
   PubMed Web of Science ®Google Scholar
• McNab AA, Galbraith JE, Friebel J, Caesar R. Pre-Whitnall levator recession with hang-back sutures in Graves orbitopathy. Ophthal. Plast. Reconstr. Surg. 20(4), 301–307 (2004).
   PubMed Web of Science ®Google Scholar
• Tucker SM, Collin R. Repair of upper eyelid retraction: a comparison between adjustable and non-adjustable sutures. Br. J. Ophthalmol. 79(7), 658–660 (1995).
   PubMed Web of Science ®Google Scholar
• Schaefer DP. The graded levator hinge procedure for the correction of upper eyelid retraction (an American Ophthalmological Society thesis). Trans. Am. Ophthalmol. Soc. 105, 481–512 (2007).
   PubMedGoogle Scholar
• Elner VM, Hassan AS, Frueh BR. Graded full-thickness anterior blepharotomy for upper eyelid retraction. Trans. Am. Ophthalmol. Soc. 101, 67–73; discussion 73 (2003).
   PubMedGoogle Scholar
• Looi AL, Sharma B, Dolman PJ. A modified posterior approach for upper eyelid retraction. Ophthal. Plast. Reconstr. Surg. 22(6), 434–437 (2006).
   PubMed Web of Science ®Google Scholar
• Velasco e Cruz AA and Vagner de Oliveira M. The effect of Müllerectomy on Kocher sign. Ophthal. Plast. Reconstr. Surg. 17(5), 309–315; discussion 315–316 (2001).
   PubMed Web of Science ®Google Scholar
• Uddin JM, Davies PD. Treatment of upper eyelid retraction associated with thyroid eye disease with subconjunctival botulinum toxin injection. Ophthalmology 109(6), 1183–1187 (2002).
   PubMed Web of Science ®Google Scholar
• Salour H, Bagheri B, Aletaha M et al. Transcutaneous dysport injection for treatment of upper eyelid retraction associated with thyroid eye disease. Orbit 29(2), 114–118 (2010).
   PubMedGoogle Scholar
• Gardner TA, Kennerdell JS, Buerger GF. Treatment of dysthyroid lower lid retraction with autogenous tarsus transplants. Ophthal. Plast. Reconstr. Surg. 8(1), 26–31 (1992).
   PubMed Web of Science ®Google Scholar
• Schittkowski MP, Fichter N, Guthoff RF. [Autogenous tarsus transplant as spacer for treatment of lower lid retraction in Grave’s disease]. Klin. Monbl. Augenheilkd. 225(8), 708–712 (2008).
   PubMed Web of Science ®Google Scholar
• Oestreicher JH, Pang NK, Liao W. Treatment of lower eyelid retraction by retractor release and posterior lamellar grafting: an analysis of 659 eyelids in 400 patients. Ophthal. Plast. Reconstr. Surg. 24(3), 207–212 (2008).
   PubMed Web of Science ®Google Scholar
• Chang HS, Lee D, Taban M, Douglas RS, Goldberg RA. ‘En-glove’ lysis of lower eyelid retractors with AlloDerm and dermis-fat grafts in lower eyelid retraction surgery. Ophthal. Plast. Reconstr. Surg. 27(2), 137–141 (2011).
   PubMed Web of Science ®Google Scholar
• Mourits MP, Koornneef L. Lid lengthening by sclera interposition for eyelid retraction in Graves’ ophthalmopathy. Br. J. Ophthalmol. 75(6), 344–347 (1991).
   PubMed Web of Science ®Google Scholar
• Feldman KA, Putterman AM, Farber MD. Surgical treatment of thyroid-related lower eyelid retraction: a modified approach. Ophthal. Plast. Reconstr. Surg. 8(4), 278–286 (1992).
   PubMed Web of Science ®Google Scholar
• Olver JM, Rose GE, Khaw PT, Collin JR. Correction of lower eyelid retraction in thyroid eye disease: a randomised controlled trial of retractor tenotomy with adjuvant antimetabolite versus scleral graft. Br. J. Ophthalmol. 82(2), 174–180 (1998).
   PubMed Web of Science ®Google Scholar
• Downes RN, Jordan K. The surgical management of dysthyroid related eyelid retraction using Mersilene mesh. Eye (Lond.) 3(Pt 4), 385–390 (1989).
   PubMed Web of Science ®Google Scholar
• Tan J, Olver J, Wright M, Maini R, Neoh C, Dickinson AJ. The use of porous polyethylene (Medpor) lower eyelid spacers in lid heightening and stabilisation. Br. J. Ophthalmol. 88(9), 1197–1200 (2004).
   PubMed Web of Science ®Google Scholar
• Malhotra R, Selva D. Free tarsus autogenous graft struts for lower eyelid elevation. Ophthal. Plast. Reconstr. Surg. 21(2), 117–122 (2005).
   PubMed Web of Science ®Google Scholar
• Goldberg RA, Lee S, Jayasundera T, Tsirbas A, Douglas RS, McCann JD. Treatment of lower eyelid retraction by expansion of the lower eyelid with hyaluronic Acid gel. Ophthal. Plast. Reconstr. Surg. 23(5), 343–348 (2007).
   PubMed Web of Science ®Google Scholar